Charles River Laboratories International, Inc. (NYSE:CRL) Position Boosted by LS Investment Advisors LLC

LS Investment Advisors LLC boosted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 17.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,971 shares of the medical research company’s stock after buying an additional 580 shares during the period. LS Investment Advisors LLC’s holdings in Charles River Laboratories International were worth $402,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Envestnet Asset Management Inc. increased its position in shares of Charles River Laboratories International by 41.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,785 shares of the medical research company’s stock valued at $135,000 after buying an additional 526 shares during the last quarter. MAI Capital Management purchased a new position in shares of Charles River Laboratories International during the first quarter valued at $224,000. Massmutual Trust Co. FSB ADV increased its position in shares of Charles River Laboratories International by 5.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,739 shares of the medical research company’s stock valued at $246,000 after buying an additional 130 shares during the last quarter. Charter Trust Co. increased its position in shares of Charles River Laboratories International by 4.6% in the first quarter. Charter Trust Co. now owns 3,030 shares of the medical research company’s stock valued at $272,000 after buying an additional 134 shares during the last quarter. Finally, Eqis Capital Management Inc. purchased a new position in shares of Charles River Laboratories International during the first quarter valued at $311,000. 95.81% of the stock is owned by hedge funds and other institutional investors.

Shares of Charles River Laboratories International, Inc. (NYSE CRL) opened at 97.97 on Friday. Charles River Laboratories International, Inc. has a 52-week low of $67.20 and a 52-week high of $102.32. The firm has a market cap of $4.66 billion, a P/E ratio of 25.82 and a beta of 1.02. The company’s 50-day moving average is $99.80 and its 200-day moving average is $91.67.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The company had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. During the same quarter last year, the firm earned $1.20 EPS. Charles River Laboratories International’s revenue for the quarter was up 8.1% compared to the same quarter last year. Equities research analysts forecast that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its Board of Directors has approved a stock buyback plan on Wednesday, May 10th that authorizes the company to repurchase $150.00 million in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: This story was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.com-unik.info/2017/08/12/charles-river-laboratories-international-inc-nysecrl-position-raised-by-ls-investment-advisors-llc-updated.html.

Several research analysts recently weighed in on CRL shares. Zacks Investment Research raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 target price for the company in a research note on Wednesday, July 12th. Jefferies Group LLC reaffirmed a “buy” rating and set a $121.00 price objective on shares of Charles River Laboratories International in a research note on Friday, June 30th. BidaskClub downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Barclays PLC reaffirmed a “hold” rating and set a $102.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and set a $95.00 price objective (up previously from $89.00) on shares of Charles River Laboratories International in a research note on Tuesday, June 6th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. Charles River Laboratories International presently has an average rating of “Hold” and an average price target of $96.94.

In other news, Director George Massaro sold 3,830 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $100.81, for a total transaction of $386,102.30. Following the sale, the director now owns 18,731 shares of the company’s stock, valued at approximately $1,888,272.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Ross Smith sold 945 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, June 8th. The stock was sold at an average price of $95.00, for a total value of $89,775.00. Following the sale, the insider now directly owns 14,203 shares in the company, valued at approximately $1,349,285. The disclosure for this sale can be found here. Insiders have sold a total of 79,369 shares of company stock worth $7,846,412 in the last three months. 2.20% of the stock is owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

What are top analysts saying about Charles River Laboratories International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Charles River Laboratories International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit